Indo Rama Synthetics (India) Ltd: Intrinsic Value & Share Price Analysis

Share Price and Basic Stock Data

Last Updated: August 8, 2025, 2:51 pm

Quick Insight

Indo Rama Synthetics (India) Ltd is currently trading at ₹51.4, reflecting a market capitalization of ₹1,341 crore and a staggering P/E ratio of 549, which raises concerns about overvaluation, especially given its low return on equity (ROE) of just 0.66% and a return on capital employed (ROCE) of 9.94%. The company's operating profit margin (OPM) stands at 7%, while it struggles with a negative interest coverage ratio (ICR) of -0.24x, indicating potential difficulties in meeting debt obligations, given its borrowings of ₹1,136 crore against reserves of only ₹107 crore. With a promoter holding of 74.84% and minimal foreign institutional investment (FIIs) at 0.01%, the stock's liquidity could be a concern. Investors should approach this stock with caution, as these metrics suggest potential risks that may outweigh the current share price allure.

Competitors of Indo Rama Synthetics (India) Ltd

All Competitor Stocks of Indo Rama Synthetics (India) Ltd

Quarterly Result

Last Updated: May 31, 2025, 8:52 am

Below is a detailed analysis of the quarterly data for Indo Rama Synthetics (India) Ltd based on the most recent figures (Mar 2025) and their trends compared to the previous period:

• For Sales, as of Mar 2025, the value is 1,198.00 Cr.. The value appears strong and on an upward trend. It has increased from 1,166.00 Cr. (Dec 2024) to 1,198.00 Cr., marking an increase of 32.00 Cr..
• For Expenses, as of Mar 2025, the value is 1,116.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 1,102.00 Cr. (Dec 2024) to 1,116.00 Cr., marking an increase of 14.00 Cr..
• For Operating Profit, as of Mar 2025, the value is 82.00 Cr.. The value appears strong and on an upward trend. It has increased from 63.00 Cr. (Dec 2024) to 82.00 Cr., marking an increase of 19.00 Cr..
• For OPM %, as of Mar 2025, the value is 7.00%. The value appears strong and on an upward trend. It has increased from 5.00% (Dec 2024) to 7.00%, marking an increase of 2.00%.
• For Other Income, as of Mar 2025, the value is 23.00 Cr.. The value appears strong and on an upward trend. It has increased from 2.00 Cr. (Dec 2024) to 23.00 Cr., marking an increase of 21.00 Cr..
• For Interest, as of Mar 2025, the value is 42.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 40.00 Cr. (Dec 2024) to 42.00 Cr., marking an increase of 2.00 Cr..
• For Depreciation, as of Mar 2025, the value is 12.00 Cr.. The value appears to be improving (decreasing) as expected. It has decreased from 13.00 Cr. (Dec 2024) to 12.00 Cr., marking a decrease of 1.00 Cr..
• For Profit before tax, as of Mar 2025, the value is 51.00 Cr.. The value appears strong and on an upward trend. It has increased from 14.00 Cr. (Dec 2024) to 51.00 Cr., marking an increase of 37.00 Cr..
• For Tax %, as of Mar 2025, the value is 0.00%. The value remains steady. There is no change compared to the previous period (Dec 2024) which recorded 0.00%.
• For Net Profit, as of Mar 2025, the value is 51.00 Cr.. The value appears strong and on an upward trend. It has increased from 14.00 Cr. (Dec 2024) to 51.00 Cr., marking an increase of 37.00 Cr..
• For EPS in Rs, as of Mar 2025, the value is 1.96. The value appears strong and on an upward trend. It has increased from 0.52 (Dec 2024) to 1.96, marking an increase of 1.44.

Overall, while many items appear to show a positive trend, any significant downward movement warrant further investigation.

Profit & Loss - Annual Report

Last Updated: July 22, 2025, 3:38 pm

Growth

Last Updated: Unknown

Balance Sheet

Last Updated: July 25, 2025, 3:01 pm

Below is a detailed analysis of the balance sheet data for Indo Rama Synthetics (India) Ltd based on the most recent figures (Mar 2025) and their trends compared to the previous period:

• For Equity Capital, as of Mar 2025, the value is 261.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2024) which recorded 261.00 Cr..
• For Reserves, as of Mar 2025, the value is 107.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2024) which recorded 107.00 Cr..
• For Borrowings, as of Mar 2025, the value is 1,136.00 Cr.. The value appears to be improving (decreasing). However, Borrowings exceed Reserves, which may signal higher financial risk. It has decreased from 1,339.00 Cr. (Mar 2024) to 1,136.00 Cr., marking a decrease of 203.00 Cr..
• For Other Liabilities, as of Mar 2025, the value is 1,431.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 1,199.00 Cr. (Mar 2024) to 1,431.00 Cr., marking an increase of 232.00 Cr..
• For Total Liabilities, as of Mar 2025, the value is 2,936.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 2,907.00 Cr. (Mar 2024) to 2,936.00 Cr., marking an increase of 29.00 Cr..
• For Fixed Assets, as of Mar 2025, the value is 1,264.00 Cr.. The value appears strong and on an upward trend. It has increased from 1,217.00 Cr. (Mar 2024) to 1,264.00 Cr., marking an increase of 47.00 Cr..
• For CWIP, as of Mar 2025, the value is 36.00 Cr.. The value appears to be declining and may need further review. It has decreased from 105.00 Cr. (Mar 2024) to 36.00 Cr., marking a decrease of 69.00 Cr..
• For Investments, as of Mar 2025, the value is 0.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2024) which recorded 0.00 Cr..
• For Other Assets, as of Mar 2025, the value is 1,636.00 Cr.. The value appears strong and on an upward trend. It has increased from 1,584.00 Cr. (Mar 2024) to 1,636.00 Cr., marking an increase of 52.00 Cr..
• For Total Assets, as of Mar 2025, the value is 2,936.00 Cr.. The value appears strong and on an upward trend. It has increased from 2,907.00 Cr. (Mar 2024) to 2,936.00 Cr., marking an increase of 29.00 Cr..

However, the Borrowings (1,136.00 Cr.) are higher than the Reserves (107.00 Cr.), which may signal higher financial risk.

Overall, while many items appear to show a positive trend, any significant downward movement or items where Borrowings exceed Reserves warrant further investigation.

Cash Flow

Free Cash Flow

Share Holding Pattern

Key Financial Ratios

After reviewing the key financial ratios for Indo Rama Synthetics (India) Ltd, here is a detailed analysis based on the latest available data and recent trends:

• For FaceValue, as of Mar 24, the value is 10.00. This value is within the healthy range. There is no change compared to the previous period (Mar 23) which recorded 10.00.
• For Basic EPS (Rs.), as of Mar 24, the value is -7.79. This value is below the healthy minimum of 5. It has decreased from -0.94 (Mar 23) to -7.79, marking a decrease of 6.85.
• For Diluted EPS (Rs.), as of Mar 24, the value is -7.79. This value is below the healthy minimum of 5. It has decreased from -0.94 (Mar 23) to -7.79, marking a decrease of 6.85.
• For Cash EPS (Rs.), as of Mar 24, the value is -6.29. This value is below the healthy minimum of 3. It has decreased from 0.25 (Mar 23) to -6.29, marking a decrease of 6.54.
• For Book Value[Excl.RevalReserv]/Share (Rs.), as of Mar 24, the value is 14.10. It has decreased from 21.93 (Mar 23) to 14.10, marking a decrease of 7.83.
• For Book Value[Incl.RevalReserv]/Share (Rs.), as of Mar 24, the value is 14.10. It has decreased from 21.93 (Mar 23) to 14.10, marking a decrease of 7.83.
• For Revenue From Operations / Share (Rs.), as of Mar 24, the value is 148.34. It has decreased from 156.44 (Mar 23) to 148.34, marking a decrease of 8.10.
• For PBDIT / Share (Rs.), as of Mar 24, the value is -1.25. This value is below the healthy minimum of 2. It has decreased from 2.54 (Mar 23) to -1.25, marking a decrease of 3.79.
• For PBIT / Share (Rs.), as of Mar 24, the value is -2.75. This value is below the healthy minimum of 0. It has decreased from 1.34 (Mar 23) to -2.75, marking a decrease of 4.09.
• For PBT / Share (Rs.), as of Mar 24, the value is -7.79. This value is below the healthy minimum of 0. It has decreased from -0.94 (Mar 23) to -7.79, marking a decrease of 6.85.
• For Net Profit / Share (Rs.), as of Mar 24, the value is -7.79. This value is below the healthy minimum of 2. It has decreased from -0.94 (Mar 23) to -7.79, marking a decrease of 6.85.
• For NP After MI And SOA / Share (Rs.), as of Mar 24, the value is -7.79. This value is below the healthy minimum of 2. It has decreased from -0.94 (Mar 23) to -7.79, marking a decrease of 6.85.
• For PBDIT Margin (%), as of Mar 24, the value is -0.84. This value is below the healthy minimum of 10. It has decreased from 1.62 (Mar 23) to -0.84, marking a decrease of 2.46.
• For PBIT Margin (%), as of Mar 24, the value is -1.85. This value is below the healthy minimum of 10. It has decreased from 0.85 (Mar 23) to -1.85, marking a decrease of 2.70.
• For PBT Margin (%), as of Mar 24, the value is -5.25. This value is below the healthy minimum of 10. It has decreased from -0.60 (Mar 23) to -5.25, marking a decrease of 4.65.
• For Net Profit Margin (%), as of Mar 24, the value is -5.25. This value is below the healthy minimum of 5. It has decreased from -0.60 (Mar 23) to -5.25, marking a decrease of 4.65.
• For NP After MI And SOA Margin (%), as of Mar 24, the value is -5.25. This value is below the healthy minimum of 8. It has decreased from -0.60 (Mar 23) to -5.25, marking a decrease of 4.65.
• For Return on Networth / Equity (%), as of Mar 24, the value is -55.26. This value is below the healthy minimum of 15. It has decreased from -4.28 (Mar 23) to -55.26, marking a decrease of 50.98.
• For Return on Capital Employeed (%), as of Mar 24, the value is -8.97. This value is below the healthy minimum of 10. It has decreased from 2.91 (Mar 23) to -8.97, marking a decrease of 11.88.
• For Return On Assets (%), as of Mar 24, the value is -6.99. This value is below the healthy minimum of 5. It has decreased from -0.90 (Mar 23) to -6.99, marking a decrease of 6.09.
• For Long Term Debt / Equity (X), as of Mar 24, the value is 0.99. This value is within the healthy range. It has increased from 0.97 (Mar 23) to 0.99, marking an increase of 0.02.
• For Total Debt / Equity (X), as of Mar 24, the value is 3.58. This value exceeds the healthy maximum of 1. It has increased from 1.51 (Mar 23) to 3.58, marking an increase of 2.07.
• For Asset Turnover Ratio (%), as of Mar 24, the value is 1.38. It has decreased from 1.70 (Mar 23) to 1.38, marking a decrease of 0.32.
• For Current Ratio (X), as of Mar 24, the value is 0.60. This value is below the healthy minimum of 1.5. It has decreased from 0.85 (Mar 23) to 0.60, marking a decrease of 0.25.
• For Quick Ratio (X), as of Mar 24, the value is 0.32. This value is below the healthy minimum of 1. It has decreased from 0.43 (Mar 23) to 0.32, marking a decrease of 0.11.
• For Inventory Turnover Ratio (X), as of Mar 24, the value is 4.62. This value is within the healthy range. It has decreased from 5.12 (Mar 23) to 4.62, marking a decrease of 0.50.
• For Interest Coverage Ratio (X), as of Mar 24, the value is -0.24. This value is below the healthy minimum of 3. It has decreased from 1.11 (Mar 23) to -0.24, marking a decrease of 1.35.
• For Interest Coverage Ratio (Post Tax) (X), as of Mar 24, the value is -0.54. This value is below the healthy minimum of 3. It has decreased from 0.58 (Mar 23) to -0.54, marking a decrease of 1.12.
• For Enterprise Value (Cr.), as of Mar 24, the value is 2,303.81. It has increased from 1,824.56 (Mar 23) to 2,303.81, marking an increase of 479.25.
• For EV / Net Operating Revenue (X), as of Mar 24, the value is 0.59. This value is below the healthy minimum of 1. It has increased from 0.44 (Mar 23) to 0.59, marking an increase of 0.15.
• For EV / EBITDA (X), as of Mar 24, the value is -70.43. This value is below the healthy minimum of 5. It has decreased from 27.56 (Mar 23) to -70.43, marking a decrease of 97.99.
• For MarketCap / Net Operating Revenue (X), as of Mar 24, the value is 0.26. This value is below the healthy minimum of 1. It has increased from 0.24 (Mar 23) to 0.26, marking an increase of 0.02.
• For Price / BV (X), as of Mar 24, the value is 2.76. This value is within the healthy range. It has increased from 1.78 (Mar 23) to 2.76, marking an increase of 0.98.
• For Price / Net Operating Revenue (X), as of Mar 24, the value is 0.26. This value is below the healthy minimum of 1. It has increased from 0.24 (Mar 23) to 0.26, marking an increase of 0.02.
• For EarningsYield, as of Mar 24, the value is -0.20. This value is below the healthy minimum of 5. It has decreased from -0.02 (Mar 23) to -0.20, marking a decrease of 0.18.

Overall, while many metrics show healthy performance, any figures highlighted in red or significant downward trends warrant further investigation.

Fair Value

*Investments are subject to market risks

Strength and Weakness